CD274 and plasma cell myeloma: Furthermore, although durvalumab (an anti‐PD‐L1 antibody) is currently being evaluated in combination with lenalidomide in clinical trials involving patients with newly diagnosed myeloma (NCT02685826),[33] additional long‐term followup data are not yet available to assess the impact of combined chemotherapy or immunomodulatory agents with PD‐L1 antibodies on long‐term prognostic indicators.